In August of 2003, Australia passed legislation that ensures consumers have the right to know when human embryonic stem cells or materials are used in the  development, manufacture or testing  of pharmaceutical products.  Since regulatory requirements for labeling do not give this same protection to Americans, Children of God for Life wishes to introduce the HUMAN CELL LABELING ACT (HCLA) to members of the House and Senate.

Since that time, Children of God for Life pursued other avenues of helping families and deemed that it was in our best interest to wait to introduce such legislation when the time was right.  There is NO time like the present and with the help of supporter and collaborator Edward Symkowiak  wrote the sample bill with such simplicity that utilizes neutral language though the purpose remains the same.

The intent was that no matter the political climate, this Bill could be introduced at the state level and IF the state required such labeling (much like in California prop.) then it would end up on ALL products distributed in the USA. 

However, only ONE State thus far has introduced such a bill.  The Honorable and heroic Senator Sampson of Connecticut has introduced the bill every year since 2023 and gets stuck in committee without a hearing despite the support from consumers, medical professionals, pro-life organizations.

This problem CAN be resolved by introducing this at the Federal levels. The time is NOW to get these vaccines and medicines labeled properly.  Technology is advancing at an alarming rate. As we saw with Covid, its also getting MORE complicated and we had NOT a single Vaccine or treatment that didn’t utilize aborted fetal cell lines. The refusal of these vaccines was MUCH MORE than just a safety issue, the outcry from the public was tremendous due to their moral status! The outcry of people demanding to know what they put in their bodies is stronger today than it has ever been.

The proposed legislation would provide concise information to all consumers and members of the medical profession whenever aborted fetal or embryonic material is used in a product so that alternatives may be selected in advance of purchase.  Our proposed bill does not differentiate between Adult, Fetal or Embryonic material in its proposed wording.

HCLA

Edward Szymkowiak, an educator and a Catholic pro-life advocate, wrote the proposed MODEL act below regarding the labeling of products that were either tested with or contain fetal cells or any human tissue. Any state legislature can adapt, adopt, and introduce this act.  

No person in the course of doing business in the State of _________ shall knowingly and intentionally expose any individual to a product known have been developed and/or tested with cells originating from any living or once living human tissue without giving clear and reasonable warning to such an individual and by including on the product packaging the words, “This product was developed and/or tested using human cells.” 

Further, any such product packaging shall contain an internet link to a webpage indicating at least the 1) origin of the human cells used to develop and/or test the product and 2) the method by which the cells were obtained and 3) any medical or scientific name of any used human cell based line(s).  However, such information shall not include the name of any person or body from which the cells originated.

A person who violates or threatens to violate this Act may be enjoined in any court of competent jurisdiction.

A person who has violated this Act is liable for a civil penalty not to exceed two thousand five hundred dollars ($2,500) per day for each violation in addition to any other penalty established by law. That civil penalty may be assessed and recovered in a civil action brought in any court of competent jurisdiction.

Bill introduced in Connecticut by Senator Sampson

HCLA provides the consumer with informed consent so that he/she may reject or accept a product based on the origins of the final product in accords with their conscience and/or deeply held beliefs

HCLA will resolve the issue of long delays and tedious research by organizations and consumers in obtaining information regarding products origin

HCLA opens the market to others in the industry who are willing to provide alternatives since they will be required to disclose which cell lines were used: Aborted Fetal, Human and/or Embryonic.

HCLA stimulates the economy with new jobs, new products and restores consumer confidence in government and the industry.

Package inserts are not only included with the product but are also published in the annual Physician’s Desk Reference, thus giving foreknowledge to medical professionals. Also, under the Doctrine of Informed Consent, physicians are required to provide patients with all relevant information about a proposed procedure including the nature of the procedure, the risks, the benefits and available alternative treatments.  Many physicians refuse to cooperate, based on conscience, with pharmaceuticals that utilize aborted fetal cell lines. Yet these same physicians care about the health of their patients and want those ethical alternatives that utilize ethical adult human cell lines, etc.

Current Federal Law requires clear, non-evasive language in consumer packaging under:

—US CODE: CHAPTER 39—FAIR PACKAGING AND LABELING PROGRAM

• 1451. Congressional declaration of policy

Informed consumers are essential to the fair and efficient functioning of a free market economy. Packages and their labels should enable consumers to obtain accurate information as to the quantity of the contents and should facilitate value comparisons. Therefore, it is hereby declared to be the policy of the Congress to assist consumers and manufacturers in reaching these goals in the marketing of consumer goods.

—CFR Title 21, Chapter 1, Subchapter C, Part 201:

• 201.6 Drugs; misleading statements.

(a) Among representations in the labeling of a drug which render such drug misbranded is a false or misleading representation with respect to another drug or a device or a food or cosmetic.

(b) The labeling of a drug which contains two or more ingredients may be misleading by reason, among other reasons, of the designation of such drug in such labeling by a name which includes or suggests the name of one or more but not all such ingredients, even though the names of all such ingredients are stated elsewhere in the labeling.

Sec. 201.10 Drugs: Statement of ingredients.

(a) The ingredient information required by section 502(e) of the Federal Food, Drug, and Cosmetic Act shall appear together, without any intervening written, printed, or graphic matter, except the proprietary names of ingredients, which may be included with the listing of established names, and such statements that are specifically required for certain ingredients by the act or regulations in this chapter.

(b) The term ingredient applies to any substance in the drug, whether added to the formulation as a single substance or in admixture with other substances.

(c) The labeling of a drug may be misleading by reason (among other reasons) of:

(1) The order in which the names of the ingredients present in the drug appear in the labeling, or the relative prominence otherwise given such names.

(2) Failure to reveal the proportion of, or other fact with respect to, an ingredient present in such drug, when such proportion or other fact is material in the light of the representation that such ingredient is present in such drug.

(3) The employment of a fanciful proprietary name for a drug or ingredient in such a manner as to imply that the drug or ingredient has some unique effectiveness or composition when, in fact, the drug or ingredient is a common substance, the limitations of which are readily recognized when the drug or ingredient is listed by its established name.

As of 8/1/2025 Children of God for Life has met with several Legislators and is continuing to pursue getting this Bill introduced at both the State and Federal Levels.

If you wish to help, please fill out our volunteer form.